This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00927537
First received: June 24, 2009
Last updated: September 1, 2013
Last verified: September 2013
June 24, 2009
September 1, 2013
April 2008
October 2011   (Final data collection date for primary outcome measure)
Blood pressure [ Time Frame: After 1-2 weeks, 1month, 3-4 months ]
Blood pressure [ Time Frame: After 1-2 weeks,1 month,3-4 months ]
Complete list of historical versions of study NCT00927537 on ClinicalTrials.gov Archive Site
  • Change in Mean heart rate (bpm) [ Time Frame: Baseline and 3-4 month ]
  • Change in Mean Weight (kg) [ Time Frame: Baseline and 3-4 month ]
  • Change in Mean laboratory parameters (total cholesterol, LDL, HDL, triglyceride, fasting blood glucose) [ Time Frame: Baseline and 3-4 month ]
  • Patient Medical History: Duration of hypertension, Pre-treatment of hypertension, Comorbidities and Concomitant treatment [ Time Frame: Baseline ]
  • Final evaluation of efficacy (very good, good, sufficient, insufficient) and tolerability (very good, good, sufficient, insufficient) of treatment by the physician. [ Time Frame: After 3-4 month ]
Not Provided
Not Provided
Not Provided
 
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
Data Collection on Hypertension and Its Treatment With Kinzal®/ Kinzalplus®
The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Community
Hypertension
  • Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
    Patients under daily life treatment receiving Kinzal according to local drug information.
  • Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
    Patients under daily life treatment receiving Kinzalplus according to local drug information.
  • Group 1
    Intervention: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
  • Group 2
    Intervention: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2052
October 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hypertensive patients seen by the physician requiring antihypertensive treatment

Exclusion Criteria:

  • According to the local drug information
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
 
NCT00927537
13599
KL0810CH ( Other Identifier: company internal )
No
Not Provided
Not Provided
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP